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egression of Cardiac
ypertrophy by Cyclic
uanosine Monophosphate-
ependent Protein
inase Signaling
re Myocytes Active Sources
r Mere Beneficiaries?*
oger J. Hajjar, MD, Fadi G. Akar, PHD
ew York, New York
eft ventricular hypertrophy (LVH) in response to elevated
ystemic pressure forms an adaptive mechanism that allows
he heart to maintain cardiac output in the face of external
tress. However, because hypertrophy is associated with
omplex electrophysiological, structural, molecular, me-
hanical, and metabolic remodeling (1,2), it ultimately
ecomes a leading risk factor for heart failure, arrhythmias,
nd sudden cardiac death.
See page 2021
Current treatment options for patients with hypertension
r pressure overload LVH center upon load reduction by
sing various pharmacological agents, including diuretics,
ngiotensin-converting enzyme inhibitors, and angiotensin
I receptor antagonists, as well as beta-adrenergic receptor
nd calcium-channel blockers. Despite the widespread
vailability and clinical use of these agents, the incidence of
VH remains unacceptably high. The clear unmet need to
uppress or even reverse the pathological remodeling asso-
iated with LVH has prompted researchers to develop and
est alternative approaches that target mechanistic effectors
f the disease within cardiomyocytes instead of focusing on
odulating pre-load and afterload. In recent years, a wealth
f information has been generated regarding the complex
olecular signaling cascades and feedback mechanisms that
nderlie LVH progression and regression. Importantly,
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.t
From the Cardiovascular Institute, Mount Sinai School of Medicine, New York,
ew York. All authors have reported that they have no relationships to disclose.arious endogenous negative regulators of hypertrophy have
een identified, raising the possibility for more mechanistic
pproaches for the treatment of LVH by selectively target-
ng native molecules in a tissue-specific manner. In this
ssue of the Journal, Zhang et al. (3) provide highly
ompelling evidence of the potential to target myocyte-
pecific phosphodiesterase type 5 (PDE5) expression in
rder to modulate the cardiac hypertrophic response to
ressure overload.
DE5-mediated signaling as a therapeutic target for LVH.
everal endogenous molecules have been shown to mediate
he progression or regression of cardiac hypertrophy by
ither activating or repressing complex signaling cascades
ithin cardiac myocytes (4–6). Of interest is the cyclic
uanosine monophosphate (cGMP) signaling pathway,
hich has emerged as a promising target for anti-
ypertrophic interventions. cGMP is the second messenger
or membrane-bound guanylate cyclase receptors, which
lay a central role in cardiovascular regulation and function.
GMP production in multiple cell types can be readily
timulated by inhibiting PDE levels. Notably, PDE5 inhib-
tors, such as sildenafil, which promote nitric oxide produc-
ion and smooth muscle relaxation, are highly effective in
reating erectile dysfunction. A major downstream effector
f cGMP signaling in cardiomyocytes is cGMP-dependent
rotein kinase G (PKG), which phosphorylates several
ownstream targets that profoundly affect cellular function.
n recent years, various investigators have shown that PDE5
s expressed in cardiomyocytes and can indeed regulate PKG
ctivity, raising the possibility that sildenafil may have
mportant cardiac benefits as well. Indeed, the effectiveness
f sildenafil for treating cardiovascular disorders including
schemia-reperfusion injury, doxorubicin toxicity, and LVH
as later demonstrated in a series of studies by multiple
roups (7–11). These rodent and pre-clinical studies pro-
ided the impetus for initiating a multicenter National
nstitutes of Health–sponsored clinical trial designed to test
he effectiveness of PDE5 inhibition in patients with heart
ailure and a preserved ejection fraction. Despite this im-
ressive progress, the basic biology and mechanisms under-
ying the PDE5/cGMP/PKG signaling cascade that pro-
otes or suppresses hypertrophic remodeling remains
omewhat unclear, mainly because of the fairly nonspecific
ature of the pharmacological tools used in these studies.
or example, concentration levels of sildenafil that effec-
ively reverse LVH inhibit multiple PDE isotypes, including
DE1, which is also highly expressed in the myocardium.
ore importantly, a recent report by Lukowski et al. (12)
aised important doubts regarding the molecular basis of
ildenafil-mediated LVH regression by suggesting nonmyo-
yte targets that are independent of PKG signaling and that
ay affect mitochondrial function.
re myocyte sources or targets of PDE5 mediated anti-
VH signaling? As mentioned, the controversy regarding
he mechanistic basis of LVH regression by sildenafil was
r
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Are Myocytes Active Sources or Mere Beneficiaries? December 7, 2010:2031–2ecently fueled by the elegant findings of Lukowski et al.
12) who used transgenic mouse models to test the effects of
lobal PKG deletion as well as myocyte-specific rescue of
KG expression (in the context of global gene silencing) on
he cardiac response to stress. Their findings that myocyte
KG levels (or lack thereof) did not affect stress-induced
isease progression prompted them to conclude that the
nti-hypertrophic response afforded by sildenafil was medi-
ted by other, as-yet-undefined targets, which require fur-
her investigation (12). Zhang et al. (3) present a highly
ompelling counterargument in favor of myocyte-specific
KG as an active source of LVH remodeling and regression
y taking a direct approach for the investigation of the
olecular basis of sildenafil treatment. Specifically, these
uthors created transgenic murine models that closely mim-
cked the bidirectional changes in myocardial PDE5 activity
evels observed in patients before and after chronic treat-
ent with sildenafil. This genetic approach allowed them to
irectly investigate the role of physiologically relevant
DE5 expression levels in myocytes while avoiding the
onfounding limitations associated with global gene dele-
ion strategies. Indeed, these authors found that enhance-
ent of myocyte PDE5 expression levels suppressed PKG
ctivation and worsened the cardiac response to pressure
verload at the organ, cellular, and molecular levels. Subse-
uent gene-targeted down-regulation of myocyte PDE5
evels after the development of pressure overload LVH
ffectively reversed cardiac dysfunction and associated
emodeling.
herapeutic implications: what does the future hold?
he report by Zhang et al. (3) offers several important
nsights into the mechanisms underlying LVH progression
nd regression by focusing on a key cell signaling pathway.
n doing so, these authors elegantly demonstrate how
re-clinical and clinical studies not only benefit from but
lso inform basic studies, which can then be designed to
xplore novel strategies for treating multiorgan disorders,
uch as LVH and heart failure. In this case, Zhang et al. (3)
argeted the PDE5/cGMP/PKG signaling cascade in order
o reverse cardiovascular dysfunction. In a “tour-de-force”
tudy, the authors confirmed the importance of intrinsic
yocyte-specific PKG levels in modulating the cardiac
esponse to stress. Their study further illustrates the impor-
ance of understanding the limitations and advantages of
sing transgenic mouse models that artificially alter the
xpression levels of a target gene, often with “toxic” conse-
uences. Indeed, the present report highlights the need for
chieving a comprehensive understanding of the complex
ignaling cascades that mediate disease progression/
egression within the context of physiologically relevant
lterations in the expression levels of target molecules. In a
K
pense, we have come full circle, as the “side effects” of an
nitial, disappointing attempt to treat angina pectoris using
DE5 inhibitors served as the basis for the now standard
reatment of erectile dysfunction. And in turn, the side
ffects of the erectile dysfunction treatment, coupled with a
rowing mechanistic understanding of the protective signal-
ng cascade associated with PKG activation, foreshadow
ew and exciting treatments for a range of cardiovascular
isorders. In light of the present findings (3), we can look
orward to new cardiomyocyte-specific and isotype-selective
trategies for therapeutic modulation of the cGMP-PKG
athway, potentially using targeted gene transfer approaches.
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